Quintiles Infosario Integrates Data to Eliminate Silos Within Drug Development Continuum
Quintiles announced the release of Quintiles Infosario, a business-to-business platform that enables customers to leverage data for improved collaboration and decision-making throughout the drug development process.
“Quintiles Infosario is a fully integrated platform that enables significant advances in the drug development process,” said Tom Grundstrom, Quintiles Infosario Global Head. “The technology makes it possible to turn the wealth of data that our company possesses into actionable insights for our customers. Through the platform’s intuitive user interface, key stakeholders will be able to make faster, better-informed decisions about the programs and therapies they are working on.”
Quintiles’ latest reporting and analytics technology integrates, synchronizes, and standardizes subject, operational and management data automatically across a multitude of systems. The platform transforms data and information into meaningful insights to Quintiles’ customers using a secure, web-based front end with a drill path from insight to clinical data. Quintiles Infosario’s reporting and analytics capabilities are among the first features that will be available to select customers beginning later this month.
In addition, customers can fulfill all or parts of their clinical IT system needs through Quintiles Infosario’s cloud-based Systems as a Service. Infosario combines IT provisioning, including configured systems with core clinical business process delivery. By using Systems as a Service, customers will have direct, cost-effective access to IT systems such as safety management and clinical trial management–the same systems that serve Quintiles business.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
